Development of an Orthotopic Patient-Derived Xenograft Model of Gastro-Esophageal Adenocarcinoma: A Single-Lineage Pilot Study
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27209051 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Rossella Reddavid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Torino, 10124 Torino, Italy. Hauptthemen laut MEDLINE: Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms, Esophagogastric Junction. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Ministry of Health, Ministero della Salute.
Abstract (Originalsprache)
Patient-derived xenografts (PDXs) preserve relevant histopathological and molecular characteristics of human tumors but, when implanted subcutaneously, poorly reproduce the native tumor microenvironment and patterns of metastatic dissemination. We developed a patient-derived orthotopic xenograft (PDOX) model of gastroesophageal junction (GEJ) adenocarcinoma based on the submucosal implantation of traceable tumor fragments. GFP/luciferase-labeled patient-derived GEJ adenocarcinoma organoids were propagated in mice as subcutaneous PDXs. Tumor fragments were then implanted into the gastric submucosal layer of seven NOD-SCID mice using a specifically developed surgical technique. Primary orthotopic tumor growth was qualitatively monitored longitudinally by in vivo IVIS imaging, whereas distant organ-associated bioluminescent signals were assessed ex vivo in excised organs at the experimental endpoint. Histopathological examination confirmed local orthotopic tumor growth. All procedures were completed without intraoperative or postoperative complications. Local tumor growth was observed in all xenografts. Distant organ-associated bioluminescent signals were detected in the liver and lungs, with an additional bowel-associated signal observed in one animal. These preliminary proof-of-concept findings demonstrate the technical feasibility of submucosal orthotopic implantation and longitudinal in vivo monitoring. However, given the small exploratory cohort and the use of a single patient-derived tumor lineage, the biological fidelity and generalizability of the model remain to be established in larger studies incorporating multiple independent tumors and comparative histopathological and molecular analyses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, University of Torino, 10124 Torino, Italy.
- INOC-Istituto Nazionale Oncologico Candiolo, IRCCS, 10060 Candiolo (TO), Italy.
ORCID-Profile: Rossella Reddavid, Maurizio Degiuli, Silvia Giordano, Simona Corso
Förderung
- Italian Association for Cancer Research
- Ministry of Health
- Ministero della Salute
- Italian Ministry of Health
Zitieren
APA
Reddavid, R., Degiuli, M., Orrù, C., Giordano, S., & Corso, S. (2026). Development of an Orthotopic Patient-Derived Xenograft Model of Gastro-Esophageal Adenocarcinoma: A Single-Lineage Pilot Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27209051
Vancouver
Reddavid R, Degiuli M, Orrù C, Giordano S, Corso S. Development of an Orthotopic Patient-Derived Xenograft Model of Gastro-Esophageal Adenocarcinoma: A Single-Lineage Pilot Study. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27209051
BibTeX
@article{Reddavid2026,
author = {Reddavid, Rossella and Degiuli, Maurizio and Orrù, Claudia and Giordano, Silvia and Corso, Simona},
title = {Development of an Orthotopic Patient-Derived Xenograft Model of Gastro-Esophageal Adenocarcinoma: A Single-Lineage Pilot Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27209051}
}
EUVIMED